Birkenfeld, March 24, 2010

In view of the current and expected future business performance of the STRATEC Group, the Board of Management of STRATEC Biomedical Systems AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard) today resolved to present to the Supervisory Board a proposal for the appropriation of profits for the Annual General Meeting which foresees raising the dividend for the 2009 financial year by 29% to Euro 0.45 per share (previous year: Euro 0.35).

 

Information and notes concerning this ad-hoc announcement:

Forthcoming publication dates

The final approved figures for the 2009 financial year will be published on April 13, 2010 and will be discussed in the annual results teleconference for analysts, investors and press representatives. The 2009 Annual Report will also be available for downloading from the company’s internet site on April 13, 2010.

The Annual General Meeting of STRATEC Biomedical Systems AG will be held in Pforzheim on Friday, May 21, 2010. The invitation to the Annual General Meeting will be forwarded to STRATEC shareholders via their depositing banks in good time ahead of the Annual General Meeting.

The interim report as of March 31, 2010 will be published on April 28, 2010.

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.

 

Further information can be obtained from:

STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email:ir(at)stratec.com